z-logo
open-access-imgOpen Access
Reactivation risk of Hepatitis B Virus in both HBsAg negative and HBcIgG positive patients with solid malignancy. Is antiviral prophylaxis really necessary?
Author(s) -
Murat Araz,
İsmail Beypınar,
Tarık Demir,
Hacer Demir,
Mükremın Uysal
Publication year - 2019
Publication title -
medicine science | international medical journal
Language(s) - English
Resource type - Journals
ISSN - 2147-0634
DOI - 10.5455/medscience.2019.08.9009
Subject(s) - medicine , hbsag , chemotherapy , malignancy , hepatitis b virus , population , regimen , cancer , gastroenterology , stage (stratigraphy) , oncology , virus , immunology , paleontology , environmental health , biology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom